| Bioactivity | BAY-390 is a selective, across species active and brain penetrating TRPA1 inhibitor. BAY-390 inhibits hTRPA1 FLIPR, hTRPA1 Ephys, rTRPA1 FLIPR and rDRG Ephys with IC50s of 16, 82, 63 and 35 nM, respectively. BAY-390 can be used for the research of inflammation[1]. |
| Target | IC50: 16 nM (hTRPA1 FLIPR), 82 nM (hTRPA1 Ephys), 63 nM (rTRPA1 FLIPR), 35 nM (rDRG Ephys), 73 nM (mTRPA1), 68 nM (gpTRPA1), 81 nM (dogTRPA1)m, 19 nM (monkeyTRPA1) |
| Invitro | BAY-390 inhibits hTRPA1 FLIPR, hTRPA1 Ephys, rTRPA1 FLIPR and rDRG Ephys with IC50s of 16, 82, 63 and 35 nM, respectively[1].BAY-390 inhibits mTRPA1, gpTRPA1, dogTRPA1 and monkeyTRPA1 with IC50s of 73, 68, 81 and 19 nM, respectively[1]. |
| In Vivo | BAY-390 (30 and 90 mg/kg; p.o.; BID for 10 days) effects the neuropathic pain in vivo[1].BAY-390 reduces visceral pain in rat cyclophosphamide induced cystitis models[1].BAY-390 shows efficacy in inflammatory pain and neurogenic inflammation models[1]. Animal Model: |
| Name | BAY-390 |
| CAS | 2741956-55-6 |
| Formula | C13H15F4NO |
| Molar Mass | 277.26 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. |